This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pareti, F. I. Articles by Ruggeri, Z. M. Search for Related Content PubMed PubMed Citation Articles by Pareti, F. I. Articles by Ruggeri, Z. M. Related Collections Valvular heart disease Ablation/ICD/surgery Other diagnostic testing CV surgery: valvular disease Platelets

(Circulation. 2000;102:1290.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Proteolysis of von Willebrand Factor and Shear Stress–Induced Platelet Aggregation in Patients With Aortic Valve Stenosis

F. I. Pareti, MD; A. Lattuada, BSc; C. Bressi, BSc; M. Zanobini, MD; A. Sala, MD; A. Steffan, MD; Z. M. Ruggeri, MD

From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Department of Internal Medicine (F.I.P., A.L., C.B.), IRCCS Maggiore Hospital, Milan; Chair of Cardiac Surgery (M.Z.), Fondazione Monzino, Milan; Division of Cardiac Surgery (A. Sala), Ospedale di Circolo, Fondazione Macchi, Varese; and the Departments of Blood Transfusion and Clinical Pathology (A. Steffan), IRCCS-CRO, Aviano, Italy; and the Departments of Molecular and Experimental Medicine and of Vascular Biology (Z.M.R.), The Scripps Research Institute, La Jolla, Calif.

Correspondence to F.I. Pareti, Department of Internal Medicine, University of Milan, Via Pace 9, 20122 Milan, Italy. E-mail Francesco.Pareti{at}unimi.it

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Excessive bleeding may complicate congenital cardiac defects. To explain the pathogenesis of this abnormality, we evaluated selected parameters of primary hemostasis in patients with aortic valve stenosis before and after corrective surgery.

Methods and Results—We examined shear-induced platelet aggregation with the filter aggregometer test and von Willebrand factor (vWF) structure by evaluating the multimeric distribution and extent of subunit proteolysis. The platelet count was reduced before corrective surgery, and shear-induced platelet aggregation was impaired. Moreover, vWF multimers of higher molecular mass were decreased, and proteolytic subunit fragments were increased. After correction of the cardiac defect, all of these parameters returned to normal.

Conclusions—Alterations of vWF and platelet function may contribute to the bleeding diathesis in patients with aortic valve stenosis. Improvement after corrective surgery suggests that the passage of blood through a stenosed aortic valve may result in shear forces that induce vWF interaction with platelets in the circulation and, in turn, trigger platelet clearance, vWF degradation, and the impairment of primary hemostasis.

Key Words: von Willebrand factor • platelets • stenosis • valves

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Bleeding from gastrointestinal angiodysplasia may complicate aortic valve stenosis.^{1 2 3 4} Supportive therapy is often inadequate to control such episodes, and replacement of the stenotic valve, rather than resection of the affected bowel tract, provides the most effective treatment.⁵ In nearly all cases, the largest multimers of plasma von Willebrand factor (vWF) are decreased.^{5 6} Patients with other congenital cardiac defects, mainly of the ventricular septum, occasionally exhibit a similar abnormality.⁷ The structural alteration of vWF may be relevant in the pathogenesis of hemorrhage because large multimers are also deficient in individuals with type 2A von Willebrand disease (vWD),^{8 9} in whom bleeding from the intestinal wall, often associated with angiodysplasia,^{4 5} is a frequent complication. The vWF abnormality in type 2A vWD is caused by congenital defects^{10 11} that enhance the susceptibility of the molecule to proteolysis.¹² Under normal conditions, cleavage of a distinct bond in the vWF subunit,¹³ presumably resulting from the activity of a specific protease,^{14 15} is a physiological process that regulates the size of circulating multimers.¹⁶ Thus, vWF in normal plasma contains fragments of the 225-kDa native subunit,¹⁷ mainly with apparent molecular masses of 176 and 140 kDa, along with a minor component of 189 kDa. Patients with type 2B vWD⁸ also exhibit enhanced vWF proteolysis¹² that results from binding of a distinctly abnormal vWF to circulating platelets,¹⁸ with subsequent microaggregation and rapid clearance.¹⁹ Fragments of the vWF subunit may also be increased in individuals with certain acquired clinical conditions, mostly as a consequence of enhanced activity of specific proteolytic enzymes.^{20 21 22 23}

Blood components are subjected to increased shear stress when passing at greater than normal velocity through a stenosed aortic valve.²⁴ Such a condition may contribute to molecular changes of vWF that increase the risk of bleeding associated with this cardiac defect. Previous experimental work has indicated that shear forces resulting from the circulation of blood may be relevant in rendering vWF susceptible to proteolytic cleavage,²⁵ possibly by changing the shape of the molecule from coiled coil to elongated filament²⁶ and exposing the bond between residues Tyr842 and Met843 to specific protease activity.¹³ Moreover, high shear stress may induce binding of the high-molecular-weight multimers of plasma vWF to the platelet membrane²⁷ with subsequent aggregation.^{28 29 30} Thus, elevated shear exerts multiple effects on vWF and could account for the disappearance of the larger multimeric forms, possibly with increased subunit proteolysis, in patients with aortic valve stenosis. The purpose of the present study was to evaluate this hypothesis by analyzing the occurrence of vWF subunit degradation and the characteristics of shear-induced platelet aggregation in such individuals. The results demonstrate enhanced proteolysis of vWF associated with increased platelet turnover but decreased aggregation of circulating platelets. These anomalies, which can all contribute to a heightened hemorrhagic risk, were reversed by surgical correction of the stenotic valve.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patients
Twenty-two patients, 9 men and 13 women between the ages of 37 and 84 years (mean, 65 years), with stenosis of the aortic valve were enrolled in the study. All underwent evaluation before and 6 months after corrective surgery. For shear-induced platelet aggregation experiments, the patients were compared with 48 healthy volunteers aged between 24 and 86 years (mean, 61 years). All patients and control subjects signed an informed consent, according to the Declaration of Helsinki, after approval of the protocol by the Ethics Committee of the University of Milan. Blood for testing vWF antigen (vWF:Ag) as well as multimer and subunit structure was collected from an antecubital vein into a polypropylene tube containing a 1/10 final volume of an anticoagulant and protease inhibitor mixture, to yield 125 mmol/L trisodium citrate, 5 mmol/L EDTA, and 6 mmol/L N-ethylmaleimide. This blood was centrifuged at 3600g for 20 minutes, and the resulting plasma was frozen in ethanol/dry ice and stored at -70°C until tested. Shear-induced platelet aggregation was evaluated with 20 mL of whole blood collected into polypropylene tubes containing 500 U/mL of recombinant hirudin (HV1, IKETON Farmaceutici Srl) and tested within 3 hours of collection. Cells were counted with an automated instrument (Coulter T-890, Instrumentation Laboratory) in 5 mL of whole blood containing EDTA.

Measurements of vWF
Plasma vWF:Ag was measured with an enzyme immunoassay with the monoclonal antibody LJ-C3 (10 µg/mL) for capture and the peroxidase-conjugated monoclonal antibody LJ-2.2.9 (5 µg/mL) for detection.³¹ The concentration of vWF was calculated from a standard curve obtained with pooled, normal plasma.³¹ The multimeric structure of vWF was evaluated by SDS-agarose gel electrophoresis on a low-resolution gel system (0.8% low-gelling-temperature agarose). The percentage of high-molecular-weight multimers was calculated by computerized scanning autoradiography (Cliniscan, Helena Laboratories), as published.³² To evaluate vWF proteolysis, the protein was isolated from plasma by using the monoclonal antibody RG 5.5.72 coupled to CNBr-activated Sepharose CL 4B (Pharmacia) at a density of 4 mg of IgG per milliliter of beads, as described.¹² Purified vWF was reduced with 65 mmol/L DTT in the presence of 2% SDS for 15 minutes at 69°C. Electrophoresis was performed in 5% SDS-polyacrylamide gels. The protein was then transferred to nitrocellulose membranes, incubated with a pool of monoclonal antibodies directed against multiple epitopes in vWF,¹⁷ and visualized with ¹²⁵I-labeled rabbit anti-mouse IgG. Samples were also probed with the monoclonal antibodies M7 and M31, which react with epitopes located between Lys185 and Met288 or Leu1481 and Met1693, respectively.³³ In the presence of reduced vWF from normal plasma, both antibodies bind to the intact subunit of 225 kDa. Moreover, antibody M7 specifically recognizes the normal proteolytic fragment of 140 kDa and the fragment of 176 kDa generated by plasmin digestion of vWF. Antibody M31 specifically recognizes the normal proteolytic fragments of 189 and 176 kDa as well as the fragment of 145 kDa generated by plasmin digestion.³³ Numbering of vWF residues is given here according to the sequence of the mature subunit, from which numbering according to the sequence of the pre–pro-vWF precursor is obtained by adding 763. All stated molecular masses are apparent as calculated from relative mobility in SDS-polyacrylamide gels. The relative proportion of vWF fragments was determined by excising individual bands from the nitrocellulose membrane, using the autoradiograph as a template, counting the corresponding radioactivity, and expressing it as a percentage of the total counts from all bands.

Shear-Induced Platelet Aggregation
This measurement was performed as previously described by O’Brien and Salmon.³⁴ Five milliliters of whole blood containing hirudin was pushed through the capillary-size channels of polycarbonate glass fibers (Pall U100, Pall Process Filtration) at a constant pressure of 100 mm Hg. The glass fibers have a diameter ranging from 0.1 to 3.4 µm, and the filter retains particles having a diameter >10 µm. The drops of blood passing through the filter in 20 seconds were enumerated by an automatic drop counter and collected into tubes containing EDTA. The percentage of retained platelets was calculated from the counts in blood before and after passage through the filter.

Glycocalicin Assay
Plasma glycocalicin (GC) was measured as previously described.³⁵ Values were expressed both as concentration in platelet-poor plasma and as an index relative to the platelet count [GC index=sample GC concentration in µg/mLx(250x10⁹/L)/(sample platelet count)].

Statistical Methods
Comparisons between measurements before and after surgery were performed with Student’s t test for paired values, with the assumption that the differences between the paired observations were normally distributed. We based our approach on the consideration that before and after measurements are commonly acknowledged to be naturally paired data.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Structure of Plasma vWF in Patients With Aortic Valve Stenosis
The concentration of plasma vWF:Ag was within normal limits in all patients tested before correction of the aortic valve stenosis (Figure 1). After surgery, a significant increase was observed in all but 4 of the 22 cases studied, in whom the vWF:Ag concentration actually decreased (Figure 1). In all individuals, the corresponding values remained within the normal range except in 2 cases, in whom plasma vWF was above the upper limit of normal (Figure 1). By comparison, there was no significant difference in the plasma concentration of fibrinogen tested before and after surgery (data not shown), indicating that the changes in vWF were not a reflection of a generalized disturbance of plasma proteins.

View larger version (22K): [in this window] [in a new window]   Figure 1. Plasma vWF:Ag measured in 22 patients with aortic valve stenosis before () and 6 months after (•) corrective surgery. Difference between 2 values was highly significant (P<0.001). Broken lines indicate upper and lower limits of normal range of measurements in our laboratory.

The relative proportion of large vWF multimers was significantly decreased in most patients before treatment, but complete correction of this defect was observed 6 months after valve replacement (Figure 2A). The loss of large vWF multimers was accompanied by a decrease in the proportion of intact subunits relative to the proteolytic fragments of 176 and 140 kDa, a structural alteration that was normalized after surgical correction of the stenosis (Figure 2B). Of note, the relative proportion of the minor 189-kDa fragment remained unchanged (not shown). Immunoblotting analysis of reduced plasma vWF demonstrated that the enhanced proteolysis observed before replacement of the diseased valve generated the same vWF subunit fragments seen in normal plasma, without evidence for novel species with distinct immunochemical characteristics (Figure 3).

View larger version (19K): [in this window] [in a new window]   Figure 2. Relative proportion of high-molecular-weight multimers (A) and subunit fragments (B) of vWF in patients with aortic valve stenosis before () and 6 months after (•) corrective surgery. In A, vWF multimers were analyzed by agarose gel electrophoresis and autoradiography after reaction with 125I-labeled anti-vWF antibody. Multimers with mobility slower than arbitrary limit were defined as large, and area that they occupied was expressed as percentage of that occupied by all multimers. In B, radioactivity associated with 125I-labeled anti-vWF monoclonal antibodies bound to reduced vWF subunit and fragments was measured after SDS-polyacrylamide gel electrophoresis and immunoblotting. Corresponding value for each band was expressed as percentage of total. Normal vWF subunit is indicated with apparent molecular mass of 225 kDa and its main amino-terminal and carboxyl-terminal proteolytic fragments with apparent molecular masses of 140 and 176 kDa, respectively. Difference between before and after surgery was highly significant in all cases (P<0.001). Broken horizontal lines indicate mean±2SD of values for 20 normal plasma samples.

View larger version (54K): [in this window] [in a new window]   Figure 3. Subunit composition of plasma vWF from control subject (NP) and 2 patients (P) with aortic valve stenosis before surgery. Immunoblotting analysis was performed with specific monoclonal antibodies after SDS-polyacrylamide gel electrophoresis of reduced, affinity-purified plasma vWF. A, Protein bands were visualized with pool of monoclonal antibodies that reacted with distinct epitopes located along entire length of mature vWF subunit. B, Protein bands were visualized with antibody that recognizes epitope located between residues Lys185 and Met288 in CNBr fragment M7 of mature vWF subunit.12 36 C, Protein bands were visualized with antibody that recognizes epitope located between residues Leu1481 and Met1693 in CNBr fragment M31 of mature vWF subunit.12 36 Note that same vWF-related bands were present in normal and patient plasma. Results shown here are representative of all patients studied.

Platelet Function in Patients With Aortic Valve Stenosis
The platelet count was significantly increased (P<0.05) after correction of the aortic valve stenosis but remained within normal limits (Figure 4A). There was no difference in leukocyte and red blood cell count before or after surgery (data not shown). The plasma concentration of soluble GC, a marker for platelet membrane destruction, was determined in 17 patients before and after valve replacement and was found to be within normal limits in both instances (Figure 4B). Shear-induced platelet aggregation was significantly increased after correction of the aortic valve stenosis, and this was particularly true for the patients whose values were outside the normal range before surgery (Figure 5). The enhanced function after valve replacement was evident both as an increase in the percentage of retained platelets and as a decrease in the amount of blood flowing through a device in which blood was pushed through a filter under conditions generating elevated shear stress (Figure 5).

View larger version (28K): [in this window] [in a new window]   Figure 4. A, Platelet counts in blood of 22 patients with aortic valve stenosis before () and 6 months after (•) corrective surgery. Difference between 2 groups was significant (Student’s t test for paired values, P<0.001). Broken horizontal lines show mean±2SD of 50 normal plasma samples. B, GC concentration tested in plasma of 17 patients before () and 6 months after (•) surgery. Results are expressed as arbitrary index that correlates GC concentration and platelet count (see Methods). Difference between before and after surgery was not significant (P>0.1). Broken horizontal lines show mean±2SD of 60 normal plasma samples.

View larger version (31K): [in this window] [in a new window]   Figure 5. Shear-induced platelet aggregation in whole blood analyzed by filter aggregometer test. A, Percentage of platelets retained in filter 20 seconds after starting measurement. B, Cumulative number of blood drops passing through filter in 20 seconds. Measurements were performed in 22 patients with aortic valve stenosis before () and 6 months after (•) corrective surgery. Broken horizontal lines show mean±2SD of normal values for each measurement, established by analysis of 50 normal plasma samples. Difference between before and after surgery was highly significant (P<0.001).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
These results identify changes of vWF structure and alterations of platelet function that may contribute to a defect of primary hemostasis in patients with aortic valve stenosis. The decreased concentration of large plasma vWF multimers may reduce the interaction of platelets with exposed tissues at sites of vascular injury, because vWF with normal structure is required for platelet thrombus formation under arterial flow rate conditions.³⁷ Lack of large vWF multimers is the cause of bleeding in type 2A vWD patients, in whom defective hemostasis persists even when plasma levels of the altered, endogenous vWF are raised by treatment with desmopressin.³⁸ A normal concentration of vWF protein, therefore, is not sufficient to support platelet adhesion and aggregation if the structure of the molecule is not preserved. The majority of patients evaluated in this study had frankly reduced large vWF multimers before correction of their valvular defect, thus explaining the occurrence of a bleeding diathesis despite a total plasma vWF concentration that was within the control range.

The existence of an abnormally enhanced proteolysis of the constitutive subunit may explain the structural defect of vWF in patients with aortic valve stenosis. It is well established¹³ that a single peptide bond cleavage in the vWF subunit, between Tyr842 and Met843, leads to a significant reduction in multimer size.^{14 15 17} Of note, the subunit fragments detected in the patients had immunochemical characteristics indistinguishable from those of fragments found at lower concentrations in all normal individuals.¹² In other pathological situations, eg, acute pancreatitis and decompensated cirrhosis, enzymes such as elastase may be responsible for the digestion of vWF.²⁰ Moreover, in patients with myocardial infarction treated by thrombolytic therapy, enhanced vWF proteolysis depends on the action of plasmin.²¹ In all of these cases, the fragments of vWF subunits may be similar to the ones present in normal individuals with respect to molecular mass, but they can be differentiated by immunochemical analysis in that they originate from different regions of the subunit and contain distinct epitopes. Our findings rule out the presence of unusual vWF fragments in aortic stenosis patients and suggest that a physiological vWF-cleaving protease is involved in the pathogenesis of the bleeding tendency that appears in some of these individuals.

The correction of vWF structural abnormalities after surgical replacement of a diseased aortic valve indicates that disturbances of flow caused by the passage of blood through the constricted orifice, thereby generating high shear stress and turbulence, may be responsible at least in part for the heightened vWF proteolysis. All of the patients enrolled in our study had a pressure gradient between the left ventricle and aorta >50 mm Hg, a value at which marked hemodynamic alterations develop across the valve and corrective surgery is considered necessary. One possibility is that shear forces directly affect the molecular conformation of large vWF multimers,^{25 26} with exposure of the proteolytically sensitive bond¹³ between Tyr842 and Met843. Alternatively, but more likely in addition, blood flow with high shear rate may promote vWF A1-domain binding to platelet glycoprotein Ib, an interaction that is typically short-lived unless coupled to activation.²⁷ The immobilization of vWF on the platelet membrane may favor the formation of small aggregates that are temporarily sequestered from the circulation and promote degradation of larger multimers by action of the natural vWF-cleaving protease. The overall equilibrium of a process of this nature may explain the relative decrease in platelet count and total vWF plasma concentration observed in the patients before compared with after replacement of the stenotic valve. A similar mechanism has been proposed to explain the pathogenesis of type 2B vWD, in which large vWF multimers disappear from the plasma as a consequence of single point mutations that enhance the affinity of the A1 domain for platelet glycoprotein Ib.^{18 19} In such a situation, vWF binding to platelets in the circulation may occur even in the absence of abnormally elevated shear rates³⁹ but still leads to the formation of microaggregates, with transient platelet sequestration and multimer degradation.¹² The occurrence of these pathogenetic events is documented by the rapidly reversible thrombocytopenia that develops when the plasma concentration of type 2B vWF is acutely increased after the administration of desmopressin.⁴⁰ The relatively lower platelet count observed in the patients with aortic valve stenosis before compared with after correction of the defect is in agreement with the proposed consequences of vWF binding, although it could also be explained by direct mechanical disruption of platelets during passage through the stenotic orifice. The fact that soluble plasma GC was not increased in the samples obtained before surgery, when platelet counts were lower in the patients, favors the former hypothesis. Such a finding tends to exclude the possibility that platelet destruction, as seen in autoimmune thrombocytopenia with elevated plasma GC,³⁵ is the cause of decreased platelet counts but is compatible with the concept that reversible platelet sequestration is responsible for the phenomenon.

The measurement of shear-induced platelet aggregation ex vivo appears to be a sensitive laboratory technique to document the abnormality of platelet function caused by aortic valve stenosis. The fact that aggregation induced by the passage of blood through the filter aggregometer at high shear rates was decreased indicates that the interaction between vWF and platelets is compromised in these patients. The alteration is explained by the absence of large-molecular-mass vWF multimers, which are known to play a key role in shear-induced aggregation.²⁹ For example, when patients with type 3 severe vWD are treated to raise their plasma levels of vWF, the results of the filter aggregometer test remain abnormal if the therapeutic concentrates are deficient in large-molecular-mass multimers.^{31 41} Of note, the bleeding time measured with a template technique was normal in all patients both before and after surgery, indicating that the overall imbalance of primary hemostasis was mild. On the other hand, it is known that this test is not always an accurate predictor of a bleeding tendency,⁴² as has also been demonstrated in patients with mild vWD.^{43 44} We observed hemorrhagic complications characterized by intestinal bleeding in 2 patients with aortic valve stenosis before surgery. The parameters reflecting high-molecular-mass vWF multimer concentration and subunit proteolysis were as abnormal as those in patients without a bleeding tendency, stressing the predictable concept that alterations of vWF and platelet function are only 1 of several determinants of abnormal bleeding. Our findings, nevertheless, indicate that the treatment of hemorrhagic complications in patients awaiting valvular replacement should include the infusion of suitable concentrates to normalize the plasma levels of large vWF multimers. In these cases, a test of shear-induced platelet aggregation should be well suited for evaluating the effects of treatment.

Received December 15, 1999; revision received April 10, 2000; accepted April 17, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Greenstein RJ, McElhinney AI, Reuben D, et al. Colonic vascular ectasias and aortic stenosis: coincidence or casual relationship? Am J Surg. 1986;151:347–351.[Medline] [Order article via Infotrieve]
   
2. King RM, Pluth JR, Giuliani ER. The association of unexplained gastrointestinal bleeding with calcific aortic stenosis. Ann Thorac Surg. 1987;44:514–516.[Abstract]
   
3. Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasia after aortic valve replacement. Ann Intern Med. 1986;105:54–57.
   
4. Ramsay DM, Buist TAS, MacLeod DAD, et al. Persistent bleeding due to angiodysplasia of the gut in von Willebrand’s disease. Lancet. 1976;2:275–278.[Medline] [Order article via Infotrieve]
   
5. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992;340:35–37.[Medline] [Order article via Infotrieve]
   
6. Weinstein M, Ware JA, Troll JH, et al. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood. 1988;71:1648–1655.[Abstract/Free Full Text]
   
7. Gill JC, Wilson AD, Endres-Brooks J, et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood. 1986;67:758–761.[Abstract/Free Full Text]
   
8. Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980;65:1318–1325.
   
9. Asakura A, Harrison J, Gomperts E, et al. Type IIA von Willebrand disease with apparent recessive inheritance. Blood. 1987;69:1419–1426.[Abstract/Free Full Text]
   
10. Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemost. 1993;69:177–184.[Medline] [Order article via Infotrieve]
    
11. Nichols WC, Cooney KA, Ginsburg D, et al. von Willebrand disease. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. Baltimore, Md: Blackwell Scientific Publications; 1998:729–755.
    
12. Zimmerman TS, Dent JA, Ruggeri ZM, et al. Subunit composition of plasma von Willebrand factor: cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID and IIE). J Clin Invest. 1986;77:947–951.
    
13. Dent JA, Berkowitz SD, Ware J, et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990;87:6306–6310.[Abstract/Free Full Text]
    
14. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–4234.[Abstract/Free Full Text]
    
15. Furlan M, Robles R, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103.[Abstract/Free Full Text]
    
16. Ruggeri ZM. Structure and biosynthesis of von Willebrand factor. In: Ruggeri ZM, ed. von Willebrand Factor and the Mechanisms of Platelet Function. Berlin, Germany: Springer-Verlag/RG Landes Co; 1998.
    
17. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88:774–782.
    
18. Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med. 1980;302:1047–1051.[Abstract]
    
19. Ruggeri ZM, Mannucci PM, Federici AB, et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood. 1982;59:1272–1278.[Abstract/Free Full Text]
    
20. Federici AB, Berkowitz SD, Lattuada A, et al. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood. 1993;81:720–725.[Abstract/Free Full Text]
    
21. Federici AB, Berkowitz SD, Zimmerman TS, et al. Proteolysis of von Willebrand factor after thrombolytic agents in patients with acute myocardial infarction. Blood. 1992;79:38–44.[Abstract/Free Full Text]
    
22. Lattuada A, Mannucci PM, Chen C, et al. Transfusion requirements are correlated with the degree of proteolysis of von Willebrand factor during orthotopic liver transplantation. Thromb Haemost. 1997;78:813–819.[Medline] [Order article via Infotrieve]
    
23. Federici AB, Falanga A, Lattuada A, et al. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-trans-retinoic acid. Br J Haematol. 1996;92:733–739.[Medline] [Order article via Infotrieve]
    
24. Nygaard H, Paulsen PK, Hasenkam JM, et al. Turbulent stresses downstream of the three mechanical aortic valve prostheses in human beings. J Thorac Cardiovasc Surg. 1994;107:438–446.[Abstract/Free Full Text]
    
25. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and required calcium ion. Blood. 1996;87:4235–4244.[Abstract/Free Full Text]
    
26. Siediecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939–2950.[Abstract/Free Full Text]
    
27. Goto S, Salomon DR, Ikeda Y, et al. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem. 1995;270:23352–23361.[Abstract/Free Full Text]
    
28. Goto S, Ikeda Y, Saldivar E, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998;101:479–486.[Medline] [Order article via Infotrieve]
    
29. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456–1461.
    
30. Peterson DM, Stathopoulos NA, Giorgio TD, et al. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987;69:625–628.[Abstract/Free Full Text]
    
31. Pareti FI, Cattaneo M, Carpinelli L, et al. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test. Thromb Haemost. 1996;75:460–468.[Medline] [Order article via Infotrieve]
    
32. Mannucci PM, Moia M, Rebulla P, et al. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol. 1987;25:55–65.[Medline] [Order article via Infotrieve]
    
33. Berkowitz SD, Dent JA, Roberts J, et al. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest. 1987;79:524–531.
    
34. O’Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand’s disease. Blood. 1987;70:1354–1361.[Abstract/Free Full Text]
    
35. Steffan A, Pradella P, Cordiano I, et al. Glycocalicin in the diagnosis and management of immune thrombocytopenia. Eur J Haematol. 1998;61:77–83.[Medline] [Order article via Infotrieve]
    
36. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25:3171–3184.[Medline] [Order article via Infotrieve]
    
37. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94:657–666.[Medline] [Order article via Infotrieve]
    
38. Mannucci PM. Treatment of von Willebrand disease. Haemophilia. 1998;4:661–664.[Medline] [Order article via Infotrieve]
    
39. De Marco L, Mazzucato M, De Roia D, et al. Distinct abnormalities in the interaction of purified IIA and IIB von Willebrand factor with the two platelet binding sites GP Ib-IX and GP IIb-IIIa. J Clin Invest. 1990;86:785–792.
    
40. Holmberg L, Nilsson IM, Borge L, et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease. N Engl J Med. 1983;309:816–821.[Abstract]
    
41. Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood. 1994;83:3018–3027.[Abstract/Free Full Text]
    
42. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16:1–20.[Medline] [Order article via Infotrieve]
    
43. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69:454–459.[Abstract/Free Full Text]
    
44. Rodeghiero F, Castaman G, Ruggeri ZM, et al. The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group. Thromb Res. 1992;65:605–615.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				T. Le Tourneau, S. Susen, C. Caron, A. Millaire, S. Marechaux, A.-S. Polge, A. Vincentelli, F. Mouquet, P.-V. Ennezat, N. Lamblin, et al. Functional Impairment of Von Willebrand Factor in Hypertrophic Cardiomyopathy: Relation to Rest and Exercise Obstruction Circulation, October 7, 2008; 118(15): 1550 - 1557. [Abstract] [Full Text] [PDF]

				K. Yoshida, S. Tobe, and M. Kawata Acquired von Willebrand Disease Type IIA in Patients with Aortic Valve Stenosis. Ann. Thorac. Surg., March 1, 2006; 81(3): 1114 - 1116. [Abstract] [Full Text] [PDF]

				K. Yoshida, S. Tobe, M. Kawata, and M. Yamaguchi Acquired and Reversible von Willebrand Disease With High Shear Stress Aortic Valve Stenosis Ann. Thorac. Surg., February 1, 2006; 81(2): 490 - 494. [Abstract] [Full Text] [PDF]

				Z. Tao, Y. Peng, L. Nolasco, S. Cal, C. Lopez-Otin, R. Li, J. L. Moake, J. A. Lopez, and J.-f. Dong Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions Blood, December 15, 2005; 106(13): 4139 - 4145. [Abstract] [Full Text] [PDF]

				P. M. Mannucci Treatment of von Willebrand's Disease N. Engl. J. Med., August 12, 2004; 351(7): 683 - 694. [Full Text] [PDF]

				A. Vincentelli, S. Susen, T. Le Tourneau, I. Six, O. Fabre, F. Juthier, A. Bauters, C. Decoene, J. Goudemand, A. Prat, et al. Acquired von Willebrand Syndrome in Aortic Stenosis N. Engl. J. Med., July 24, 2003; 349(4): 343 - 349. [Abstract] [Full Text] [PDF]

				L. H. Caramuru, R. D. P. S. Soares, N. Y. Maeda, and A. A. Lopes Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 251 - 258. [Abstract] [PDF]

				P. Gresele, G. Guglielmini, M. De Angelis, S. Ciferri, M. Ciofetta, E. Falcinelli, C. Lalli, G. Ciabattoni, G. Davi, and G. B. Bolli Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus J. Am. Coll. Cardiol., March 19, 2003; 41(6): 1013 - 1020. [Abstract] [Full Text] [PDF]

				T. E. Warkentin, J. C. Moore, and D. G. Morgan Gastrointestinal Angiodysplasia and Aortic Stenosis N. Engl. J. Med., September 12, 2002; 347(11): 858 - 859. [Full Text] [PDF]

				R Rauch, U Budde, A Koch, M Girisch, and M Hofbeck Acquired von Willebrand syndrome in children with patent ductus arteriosus Heart, July 1, 2002; 88(1): 87 - 88. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pareti, F. I. Articles by Ruggeri, Z. M. Search for Related Content PubMed PubMed Citation Articles by Pareti, F. I. Articles by Ruggeri, Z. M. Related Collections Valvular heart disease Ablation/ICD/surgery Other diagnostic testing CV surgery: valvular disease Platelets